12:00 AM
 | 
Nov 23, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

PF-04523655: Completed Phase II enrollment

Quark said Pfizer completed enrollment in a single-blind Phase II trial evaluating PF-04523655 vs. laser therapy. The compound uses AtuRNAi chemistry from Silence...

Read the full 103 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >